The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Novartis announced positive, longer-term results from the pivotal phase III ASC4FIRST trial with Scemblix (asciminib) showing superior major molecular response (MMR) rates at week 961. The study ...

Enliven Therapeutics' ELVN-001 shows promising results for CML patients. Click here to read what makes ELVN stock a ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Novartis's current product portfolio and pipeline are central to its growth strategy. Key products such as Cosentyx, Pluvicto, Kisqali, and Scemblix are expected to drive the company's mid-term ...

Prominent among these are Cosentyx, Pluvicto, Kisqali, and Scemblix. These products form the backbone of the company's near-term revenue strategy and are crucial for meeting its growth targets.

Novartis (NVS) announced “positive,” longer-term results from the pivotal Phase 3 ASC4FIRST trial with Scemblix showing superior major molecular response rates at week 96. The study compared ...

NVS Presents Long-Term Data on Scemblix Novartis also announced positive, longer-term results from the phase III ASC4FIRST study on leukemia drug Scemblix (asciminib). Scemblix demonstrated ...

Cosentyx, Entresto, Kesimpta, Pluvicto, Scemblix, Zolgensma, Kisqali and Leqvio should fuel growth through 2030 and beyond. NVS sits at a Zacks Rank #2 (Buy), holds a Value Style Score of A ...

Some of Novartis AG (NYSE:NVS)’s key drugs are its prostate cancer drug Pluvicto, heart disease drug Leqvio, leukemia treatment Scemblix, and breast cancer treatment Kisqali. Among these ...

We recently compiled a list of the 10 Best European Dividend Stocks To Buy. In this article, we are going to take a look at ...